Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$682.78 USD

682.78
3,182,169

+147.24 (27.49%)

Updated Aug 4, 2025 03:59 PM ET

After-Market: $682.70 -0.08 (-0.01%) 7:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

IDEXX Stock Up on Q2 Earnings & Revenue Beat, Margins Expand

by Zacks Equity Research

IDXX posts double-digit Q2 revenue growth, beats EPS estimates and lifts the full-year outlook as margins rise sharply.

Zacks Equity Research

Idexx (IDXX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Idexx Laboratories (IDXX) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Idexx (IDXX) delivered earnings and revenue surprises of +9.67% and +4.01%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Integra LifeSciences (IART) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Integra (IART) delivered earnings and revenue surprises of +4.65% and +5.05%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Idexx (IDXX) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates

by Zacks Equity Research

Beyond analysts' top-and-bottom-line estimates for Idexx (IDXX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.

Zacks Equity Research

AxoGen (AXGN) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks Equity Research

IDEXX to Release Q2 Earnings: What's in Store for the Stock?

by Zacks Equity Research

IDXX eyes a Q2 earnings jump with CAG growth, global pricing gains, and momentum in water and software segments.

Zacks Equity Research

Should You Invest in the First Trust Water ETF (FIW)?

by Zacks Equity Research

Sector ETF report for FIW

Zacks Equity Research

Should Franklin U.S. Mid Cap Multifactor Index ETF (FLQM) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FLQM

Zacks Equity Research

Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how atai Life Sciences N.V. (ATAI) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.

Zacks Equity Research

Idexx (IDXX) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Zacks Equity Research

Here's How Much You'd Have If You Invested $1000 in Idexx Laboratories a Decade Ago

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Zacks Equity Research

Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year?

by Zacks Equity Research

Here is how atai Life Sciences N.V. (ATAI) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.

Zacks Equity Research

Should You Invest in the First Trust Water ETF (FIW)?

by Zacks Equity Research

Sector ETF report for FIW

Zacks Equity Research

Is Franklin U.S. Mid Cap Multifactor Index ETF (FLQM) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FLQM

Zacks Equity Research

If You Invested $1000 in Idexx Laboratories a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Nalak Das headshot

5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil

by Nalak Das

Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS.

Zacks Equity Research

Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Idexx Laboratories (IDXX) and AngioDynamics (ANGO) have performed compared to their sector so far this year.

Zacks Equity Research

IDXX Q1 Earnings Beat, FY25 View Raised, Stock Up in Pre-Market

by Zacks Equity Research

IDEXX delivers year-over-year earnings and revenue growth in the first quarter of 2025.

Zacks Equity Research

Compared to Estimates, Idexx (IDXX) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Idexx Laboratories (IDXX) Beats Q1 Earnings Estimates

by Zacks Equity Research

Idexx (IDXX) delivered earnings and revenue surprises of 1.37% and 1.77%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?